Due to the high cost of new HER2-ADC drugs, therapeutic strategies for treating patients with HER2-low breast cancer should be considered in the context of HR status in the context of cost-effectiveness and optimal choice, and early testing of such prognostic factors is critical. This evidence concerns the gene ERBB2 and breast carcinoma.